OmniAb (OABI) Income from Continuing Operations (2021 - 2026)
OmniAb's (OABI) quarterly Income from Continuing Operations came in at 7707000.0 in Q1 2026, up 57.65% year-on-year from 4888558.18 in Q1 2025, and up 45.64% on a QoQ basis from 14179000.0 in Q4 2025.
OmniAb (OABI) Income from Continuing Operations (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Income from Continuing Operations data on file, last reported at 7707000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 57.65% year-over-year to 7707000.0 in Q1 2026; TTM through Mar 2026 was 54286000.0, a 11.4% increase from a year earlier, with the FY2025 full-year figure at 64779000.0, down 4.43% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 7707000.0, up from 14179000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for OABI reached as high as 6820000.0 in Q4 2022 and fell as low as 18961000.0 in Q1 2024.
- Historically, Income from Continuing Operations has averaged 12204235.29 across 5 years, with a median of 14053000.0 in 2023.
- On a YoY basis, Income from Continuing Operations climbed as much as 118.97% in 2022 and fell as far as 470197.48% in 2022.
- Year by year, Income from Continuing Operations stood at 6820000.0 in 2022, then sank by 306.06% to 14053000.0 in 2023, then climbed by 7.01% to 13068000.0 in 2024, then declined by 8.5% to 14179000.0 in 2025, then surged by 45.64% to 7707000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 7707000.0 in Q1 2026, 14179000.0 in Q4 2025, and 16525000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | OmniAb | 263.54 Mn | 214.47 Mn | 14.41 Mn | -7.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.71 Mn |
| Dec 31, 2025 | -14.18 Mn |
| Sep 30, 2025 | -16.53 Mn |
| Jun 30, 2025 | -15.88 Mn |
| Mar 31, 2025 | -18.20 Mn |
| Dec 31, 2024 | -13.07 Mn |
| Sep 30, 2024 | -16.37 Mn |
| Jun 30, 2024 | -13.63 Mn |
| Mar 31, 2024 | -18.96 Mn |
| Dec 31, 2023 | -14.05 Mn |
| Sep 30, 2023 | -15.74 Mn |
| Jun 30, 2023 | -14.73 Mn |
| Mar 31, 2023 | -6.10 Mn |
| Dec 31, 2022 | 6.82 Mn |
| Sep 30, 2022 | -12.60 Mn |
| Jun 30, 2022 | -10.28 Mn |
| Mar 31, 2022 | -6.28 Mn |
| Dec 31, 2021 | -35.95 Mn |
| Sep 30, 2021 | -170,579.00 |
| Jun 30, 2021 | -2,185.00 |